Hyperlipidaemia News

  • 27 August 2019
    In the PEARL study of real-world use of alirocumab in Germany, nearly three-quarters of patients were prescribed this PCSK9 inhibitor due to statin intolerance. PEARL was an open, prospective, multicentre study including 619 patients for whom alirocumab 75 or 150 mg every 2 weeks was prescribed due to inadequately controlled LDL cholesterol levels...
  • 27 August 2019
    PCSK9 inhibitors work – but access is the problem Rejection of PCSK9 inhibitor treatment by payers significantly increases the risk of cardiovascular events in very high-risk patients in real-world practice, based on a US report. PCSK9 Forum Editor Professor Chris Packard, University of Glasgow, UK, comments that the wider message is still (as...
  • 15 August 2019
    Professor Derick Raal, University of the Witwatersrand, Johannesburg, South Africa. Patients with diabetes and a history of acute coronary syndrome (ACS) are at enhanced risk of recurrent events and death compared with those without diabetes.1 Does this mean that treatment with a PCSK9 inhibitor will provide even greater benefit in this patient...
  • 08 August 2019
    Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Jan Boren  The post Hepatic lipid metabolism: Storage vs secretion appeared first on PCSK9 Forum.
  • 01 August 2019
    An international collaboration (the ScreenPro FH Project) has improved screening for familial hypercholesterolaemia across seven countries in central, eastern and southern Europe (CESE). However, although there has been a significant increase in the numbers of patients in national registries and treatment centres, these patients are still far from...
  • 01 August 2019
    Similar alirocumab efficacy and safety across different races and ethnicities Alirocumab significantly reduced LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels compared with controls, regardless of race and ethnicity, together with overall safety comparable to control across the majority of racial and ethnic groups analysed. This post-...
  • 24 July 2019
    Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Brian Ference  The post Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins appeared first on PCSK9 Forum.
  • 24 July 2019
    Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Erik Stroes  The post New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations appeared first on PCSK9 Forum.
  • 24 July 2019
    Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Frederick Raal  The post Inclisiran: The Phase 3 trial appeared first on PCSK9 Forum.
  • 24 July 2019
    Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Peter Sever  The post FOURIER trial: Update on subgroup analyses appeared first on PCSK9 Forum.
  • 23 July 2019
    Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Andreas M Zeiher  The post ODYSSEY OUTCOMES: Update appeared first on PCSK9 Forum.
  • 17 July 2019
    Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Henry Ginsberg  The post The new AHA/ACC Treatment Guidelines: Critical appraisal appeared first on PCSK9 Forum.
  • 17 July 2019
    Reports from the 10th Closed Expert Meeting of the PCSK9 Education and Research Forum Børge Nordestgaard  The post Is it time to upgrade Lp(a) to a therapeutic target in Guidelines? appeared first on PCSK9 Forum.
  • 10 July 2019
    Alirocumab in patients without prior MI or stroke Alirocumab showed similar efficacy and tolerability in patients with or without a prior myocardial infarction (MI) or ischaemic stroke, according to this latest report. This analysis included patient-level data from 9 phase 3 ODYSSEY trials involving 4,880 patients treated with alirocumab for 24–...
  • 10 July 2019
    The post Prof Stephen Nicholls Effect of alirocumab on MI types appeared first on PCSK9 Forum.
  • 10 July 2019
    The post Novel PCSK9 therapeutics appeared first on PCSK9 Forum.
  • 10 July 2019
    Treatment with evolocumab versus placebo prevented more than double the number of total events compared with first events in this analysis of the FOURIER study. These findings align with data from ODYSSEY OUTCOMES1 and support continued benefit from aggressive LDL cholesterol lowering therapy to prevent recurrent cardiovascular events in very high...
  • 10 July 2019
    A new analysis from the FOURIER study demonstrates clinical benefit with evolocumab in chronic kidney disease (CKD), with the greatest absolute benefit in patients with more advanced disease. CKD is a global health burden with a high socioeconomic cost. European guidelines consider CKD patients to be at very high cardiovascular risk, and in the...
  • 10 July 2019
    Does alirocumab have preventive effects on MI beyond LDL cholesterol lowering? Myocardial infarction (MI) indicates irreversible myocardial injury resulting in necrosis of a significant portion of myocardium (generally >1 cm).  According to the Third Universal Definition of MI Task Force,1 MI can be categorised into one of five types (Box 1)....
  • 10 July 2019
    In 2012, there was the first clinical evidence of dramatic reductions in LDL cholesterol by inhibiting PCSK9 with the monoclonal antibodies (mAbs) evolocumab and alirocumab. This was followed in 2017 and 2018 with definitive proof from major cardiovascular outcome trials, FOURIER and ODYSSEY OUTCOMES, that PCSK9 mAb therapy reduces cardiovascular...

Pages